Partner Headlines - CPHD

  1. CEPHEID

    IBD
  2. Cepheid Receives FDA Clearance For Xpert Flu/RSV XC

    Benzinga
  3. Cepheid To Develop Xpert Ebola For Countries Worst Hit By Epidemic

    Benzinga
  4. Several Sectors Emerge As Leaders Of New Market Uptrend

    IBD
  5. Stocks Fight Back To Finish Mixed

    IBD
  6. Dow, Nasdaq Battle Near Flat Line; Energy Weighs On S&P 500

    IBD
  7. Cepheid Explores Test For Ebola Disease; Q3 Beats

    IBD
  8. CEPHEID

    IBD
  9. Cepheid Extends Reach Of Direct US Commercial Operations

    Benzinga
  10. UPDATE: ISI Group Upgrades Cepheid

    Benzinga
  11. CEPHEID

    IBD
  12. LinkedIn, TripAdvisor, Google: Top Manager's Ideas

    IBD
  13. Alexion Takes Off On Outlook

    IBD
  14. Three Medical Tech Names To Watch In Healthcare Space

    IBD
  15. Align Leads Three Top-Rated Medical Equipment Stocks

    IBD
  16. UPDATE: JMP Securities Initiates Coverage on Cepheid on Market ...

    Benzinga
  17. Five Medical Stocks Leaders Trade Near New Highs

    IBD
  18. ViroPharma Gets Bought Out; Medicines Clears Entry

    IBD
  19. UPDATE: ISI Group Downgrades Cepheid on Key Drivers Constraining ...

    Benzinga
  20. Benzinga's Top Downgrades

    Benzinga
  21. UPDATE: Bank of America Downgrades Cepheid on Fair Valuation

    Benzinga
  22. Benzinga's Top Downgrades

    Benzinga
  23. Cepheid Reports Xpert MTB/RIF Categorized 'Moderate Complexity' ...

    Benzinga
  24. Cepheid Announces Board of Directors Changes

    Benzinga
  25. Cepheid's Chlamydia and N. Gonorrhoeae Test Categorized 'Moderate ...

    Benzinga
  26. Medtech Stocks Moving As Conference Makes Waves

    IBD
  27. Medtech Stocks Moving As Conference Makes Waves

    IBD
  28. Cepheid Offers Update on Xpert Test Availability, Sees Q4 Sales ...

    Benzinga
  29. UPDATE: Piper Jaffray Downgrades Cepheid to Neutral, Lowers PT

    Benzinga
  30. Oppenheimer Holdings Reiterates Outperform Rating, $43 PT on ...

    Benzinga
  31. Canaccord Genuity Reiterates Buy Rating, $50 PT on Cepheid

    Benzinga
  32. Cantor Fitzgerald Reiterates Hold Rating, $38 PT on Cepheid

    Benzinga
  33. US Stock Futures Down Ahead Of Economic Data

    Benzinga
  34. Stocks To Watch For December 28, 2012

    Benzinga
  35. UPDATE: Cepheid Wins FDA Clearance for Xpert CT/NG

    Benzinga
  36. UPDATE: Bank of America Initiates Cepheid at Buy on Prospects, ...

    Benzinga
  37. Look At That Base: If You Can't Name It, Don't Buy It

    IBD
  38. UPDATE: Goldman Sachs Downgrades Cepheid to Neutral on Lack of ...

    Benzinga
  39. Benzinga's Top Downgrades

    Benzinga
  40. Benzinga's Top Upgrades

    Benzinga
  41. CEPHEID Reports Operating Results (10-Q)

    GuruFocus
  42. UPDATE: Cantor Fitzgerald Maintains Cepheid at Hold on Analyst ...

    Benzinga
  43. UPDATE: Canaccord Genuity Reiterates Cepheid at Buy with $50 ...

    Benzinga
  44. Goldman Sachs Reiterates Buy Rating, $46 PT on Cepheid

    Benzinga
  45. UPDATE: ISI Group Reduces PT to $30.50 on Cepheid Post Analyst ...

    Benzinga
  46. Benzinga Mid-Afternoon Market Update

    Benzinga
  47. Stock Futures Point to Higher Open with Yahoo (YHOO) and Hewlett-Packard ...

    MarketIntelligenceCenter
  48. Benzinga Mid-Day Market Update

    Benzinga
  49. Mid-Morning Market Update

    Benzinga
  50. UPDATE: ISI Group Reduces PT to $32.50 on Cepheid Following Negative ...

    Benzinga
  51. Benzinga's Top Initiations

    Benzinga
  52. A Peek Into The Market Before The Trading Starts

    Benzinga
  53. UPDATE: JP Morgan Initiates Cepheid at Overweight on Growth Outlook

    Benzinga
  54. Benzinga's Top Initiations

    Benzinga
  55. Technology Sector Wrap

    FoxBusiness
  56. Technology Sector Wrap

    FoxBusiness
  57. Technology Sector Wrap

    FoxBusiness
  58. Analyst Downgrades: Cepheid, Intuitive Surgical, and Travelzoo

    SchaeffersResearch
  59. Cepheid Down 20% on Weak Guidance

    Benzinga
  60. CEPHEID (CPHD) CEO John L Bishop sells 40,201 Shares

    GuruFocus
  61. CEPHEID (CPHD) CEO John L Bishop sells 25,000 Shares

    GuruFocus
  62. CEPHEID (CPHD) EVP, CFO Andrew Miller sells 17,437 Shares

    GuruFocus
  63. A Peek Into The Market Before The Trading Starts

    Benzinga
  64. UPDATE: UBS Investment Research Upgrades Cepheid to Buy; Opportunistic ...

    Benzinga
  65. Benzinga's Top Downgrades With Color for May 14, 2012

    Benzinga
  66. UPDATE: GARP Research & Securities Downgrades Cepheid to Neutral; ...

    Benzinga
  67. Cepheid Earnings Miss Estimates; Stock Plummets

    IBD
  68. Cepheid Q1 Estimates Soft, But Outlook For Year Good

    IBD
  69. Zoll Deal, Intutive Surgical Lift Medical Equipment

    IBD
  70. Cepheid Stock Price Rises on Strong 2012 Sales Outlook

    IBD
  71. CEPHEID Reports Operating Results (10-K)

    GuruFocus
  72. CEPHEID (CPHD) EVP, CFO Andrew Miller sells 62,062 Shares

    GuruFocus
  73. CEPHEID (CPHD) CEO John L Bishop sells 6,887 Shares

    GuruFocus
  74. CEPHEID (CPHD) Executive VP, COO Humberto Reyes sells 133,957 ...

    GuruFocus
  75. Stocks Finish Week Split; Nasdaq, S&P 500 Higher

    IBD
  76. Stocks Stay Mixed; Under Armour Clears 50-Day

    IBD
  77. RBC Capital Upgrades Cepheid to Outperform

    Benzinga
  78. UPDATE: Credit Suisse Initiates Outperform, $40 Target on Cepheid

    Benzinga
  79. Analogic Earnings Preview: EPS Expected to Double

    Benzinga
Trading Center